Replies to post #117722 on NanoViricides Inc. (NNVC)

[Nanotoday]

at least one with high probability of hitting clinical testing before the end of 2016.

They have yet to identify the initial 8 formulas to test, then reformulate and retest, and then, well you know.

This will not be completed in '16.

[JG36]

I'd change that to "at least one drug candidate with a probability of hitting clinical testing in 2016 that is no worse than me winning the Megamillions with one ticket." Here in real life we will be very lucky if Herpescide is through tox by the end of 2016. There is no realistic chance that Herpescide will be through tox, and the IND application is made, and it is approved, and a phase I trial is started, all in 2016.

There is an excellent chance that NNVC will find itself midway through 2017 with:

(1) No drug in clinical trials yet.

(2) A need to raise more money by selling more shares at whatever price the market will take.